New‐onset fulminant type 1 diabetes after severe acute respiratory syndrome coronavirus 2 vaccination: A case report |
| |
| Authors: | Keyaki Sasaki Tomoaki Morioka Natsumi Okada Yuka Natsuki Yoshinori Kakutani Akinobu Ochi Yuko Yamazaki Tetsuo Shoji Takashi Ohmura Masanori Emoto |
| |
| Affiliation: | 1. Department of Metabolism, Endocrinology, and Molecular Medicine, Osaka City University Graduate School of Medicine, Osaka Japan ; 2. Department of Internal Medicine, Asakayama General Hospital, Sakai Japan ; 3. Department of Vascular Medicine, Osaka City University Graduate School of Medicine, Osaka Japan |
| |
| Abstract: | Fulminant type 1 diabetes is characterized by a rapid progression of insulin deficiency triggered by viral infection. Here, we report a case of a 45‐year‐old Japanese woman with fulminant type 1 diabetes that developed 8 days after receiving messenger ribonucleic acid vaccine against severe acute respiratory syndrome coronavirus 2. She had been healthy and had no symptoms suggestive of viral infection before the vaccination. Laboratory tests showed exhaustion of insulin secretion and negative results for islet autoantibodies. Human leukocyte antigen genotype analysis showed the DRB1*04:05 and DQB1*04:01 alleles. This is the first case report of new‐onset fulminant type 1 diabetes after severe acute respiratory syndrome coronavirus 2 vaccination, and suggests that a severe acute respiratory syndrome coronavirus 2 vaccine might trigger the onset of fulminant type 1 diabetes in susceptible individuals. However, a causal relationship remains to be identified, and further studies are required to determine the incidence of such cases. |
| |
| Keywords: | Fulminant type 1 diabetes, Severe acute respiratory syndrome coronavirus 2, Vaccination |
|
|
